CO6690779A2 - Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación. - Google Patents

Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación.

Info

Publication number
CO6690779A2
CO6690779A2 CO13057092A CO13057092A CO6690779A2 CO 6690779 A2 CO6690779 A2 CO 6690779A2 CO 13057092 A CO13057092 A CO 13057092A CO 13057092 A CO13057092 A CO 13057092A CO 6690779 A2 CO6690779 A2 CO 6690779A2
Authority
CO
Colombia
Prior art keywords
preparation
intermediates
pan
formula
cdk inhibitors
Prior art date
Application number
CO13057092A
Other languages
English (en)
Inventor
Joachim Kruger
Jorg Gries
Kai Lovis
Jorma Hassfeld
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6690779(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CO6690779A2 publication Critical patent/CO6690779A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

La presente invención reclama un proceso para la preparación de inhibidores de pan-Ci)K con actividad antitumoral por medio de mecanismos citotóxicos de la fórmula general (I), donde R4 es un grupo CI -C6-aiquilo o un anillo C3-C7-cicioalquilo. En particular, se dirige a la preparación del compuesto (2R, 3R)-3- { [2- { [4-(S-ciclopropilsulfonimidoil)fenil]amino} -5- (trifluorometil) pirirnidin-4-iljoxi}hutan-2-ol. Este proceso es adecuado para aumentar la escala y supera las desventajas de los procesos conocidos mediante el empleo de diversos pasos de preparación e intermediarios ventajosos.Igualmente, la presente invención proporciona intermediarios de la preparación y sales.
CO13057092A 2010-09-23 2013-03-22 Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación. CO6690779A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010046720A DE102010046720A1 (de) 2010-09-23 2010-09-23 Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung

Publications (1)

Publication Number Publication Date
CO6690779A2 true CO6690779A2 (es) 2013-06-17

Family

ID=44677881

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13057092A CO6690779A2 (es) 2010-09-23 2013-03-22 Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación.

Country Status (32)

Country Link
US (1) US9359306B2 (es)
EP (1) EP2619186A1 (es)
JP (1) JP5969993B2 (es)
KR (1) KR20130109145A (es)
CN (1) CN103119026B (es)
AP (1) AP2013006816A0 (es)
AR (1) AR083171A1 (es)
AU (1) AU2011304365B2 (es)
BR (1) BR112013006720A2 (es)
CA (1) CA2811807A1 (es)
CL (1) CL2013000797A1 (es)
CO (1) CO6690779A2 (es)
CR (1) CR20130138A (es)
CU (2) CU20130044A7 (es)
DE (1) DE102010046720A1 (es)
DO (1) DOP2013000063A (es)
EC (1) ECSP13012520A (es)
GT (1) GT201300078A (es)
HK (1) HK1185615A1 (es)
IL (1) IL225352A0 (es)
MX (1) MX2013003338A (es)
MY (1) MY160625A (es)
NZ (1) NZ608448A (es)
PE (1) PE20140182A1 (es)
RU (1) RU2585621C2 (es)
SA (1) SA111320775B1 (es)
SG (1) SG188967A1 (es)
TW (1) TWI530488B (es)
UA (1) UA110626C2 (es)
UY (1) UY33624A (es)
WO (1) WO2012038411A1 (es)
ZA (1) ZA201301799B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201418243A (zh) * 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
HRP20230158T1 (hr) 2017-10-05 2023-03-31 Innovative Molecules Gmbh Enantiomeri supstituiranih tiazola kao antivirusni spojevi
WO2019158517A1 (en) 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118481A (en) * 1995-06-05 2000-08-31 Rhone Poulenc Agrochimie Sulfur compounds pesticidal compositions containing them and method of their application
EP1291336A3 (en) 2001-09-05 2003-10-08 Solvias AG Preparation of optically active alpha-hydroxyethers
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
SG188967A1 (en) 2013-05-31
RU2013118432A (ru) 2014-10-27
PE20140182A1 (es) 2014-02-14
BR112013006720A2 (pt) 2016-06-14
CU20130044A7 (es) 2013-07-31
AU2011304365A1 (en) 2013-04-11
AU2011304365B2 (en) 2015-02-05
NZ608448A (en) 2014-10-31
EP2619186A1 (de) 2013-07-31
MY160625A (en) 2017-03-15
UA110626C2 (uk) 2016-01-25
AR083171A1 (es) 2013-02-06
JP5969993B2 (ja) 2016-08-17
KR20130109145A (ko) 2013-10-07
CL2013000797A1 (es) 2013-09-13
CR20130138A (es) 2013-05-15
SA111320775B1 (ar) 2015-02-03
US20130245261A1 (en) 2013-09-19
HK1185615A1 (en) 2014-02-21
US9359306B2 (en) 2016-06-07
GT201300078A (es) 2014-11-26
TW201215596A (en) 2012-04-16
WO2012038411A1 (de) 2012-03-29
CA2811807A1 (en) 2012-03-29
IL225352A0 (en) 2013-06-27
RU2585621C2 (ru) 2016-05-27
AP2013006816A0 (en) 2013-04-30
CU20150165A7 (es) 2016-05-30
ECSP13012520A (es) 2013-05-31
DE102010046720A1 (de) 2012-03-29
TWI530488B (zh) 2016-04-21
UY33624A (es) 2012-04-30
CN103119026A (zh) 2013-05-22
DOP2013000063A (es) 2013-04-30
MX2013003338A (es) 2013-06-24
ZA201301799B (en) 2014-05-28
CN103119026B (zh) 2015-08-19
JP2013542189A (ja) 2013-11-21

Similar Documents

Publication Publication Date Title
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CU20130101A7 (es) Derivados de 1,4-oxazin-3-il-piridin-2-il-acetamida, activos como inhibidores bace-1 o bace-2
NI201300018A (es) Promotores de apoptosis de n - acilsulfonamidas
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
UY32848A (es) Compuestos heterocíclicos de oxima
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CO6480975A2 (es) Mimetico de smac
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
GT201200280A (es) Procedimiento
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CR20140553A (es) Compuestos de fenoxietil piperidina
ECSP11011485A (es) Espiro-epóxidos como productos intermedios.
CO6321288A2 (es) Sales de compuestos inhibidores de vih
EA201290558A1 (ru) Агонисты mglu2
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
CO6690779A2 (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación.
BR112014018738A8 (pt) Métodos e intermediários para preparo de agentes farmacêuticos
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.